Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Net Margin (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed Net Margin for 9 consecutive years, with 19.5% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 2955.0% to 19.5% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.84%, a 4150.0% increase, with the full-year FY2025 number at 2.26%, up 4107.0% from a year prior.
  • Net Margin was 19.5% for Q4 2025 at Akebia Therapeutics, down from 0.92% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 20.09% in Q2 2022 to a low of 159.33% in Q2 2021.
  • A 5-year average of 54.53% and a median of 41.75% in 2024 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 27760bps in 2021; the steepest drop was -6468bps in 2021.
  • Akebia Therapeutics' Net Margin stood at 122.1% in 2021, then surged by 97bps to 3.92% in 2022, then surged by 128bps to 1.09% in 2023, then plummeted by -4589bps to 49.04% in 2024, then soared by 60bps to 19.5% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Net Margin are 19.5% (Q4 2025), 0.92% (Q3 2025), and 0.4% (Q2 2025).